{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:33:44Z","timestamp":1775208824181,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.atherosclerosis.2006.12.001","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T12:19:43Z","timestamp":1169036383000},"page":"e154-e164","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study"],"prefix":"10.1016","volume":"194","author":[{"given":"Lawrence A.","family":"Leiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.D.","family":"Reckless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Ludwig","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margo","family":"Schleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Froukje","family":"Sosef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib3","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib5","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"European guidelines on cardiovascular disease prevention in clinical practice","volume":"24","author":"De Backer","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9149(03)00474-0","article-title":"Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events","volume":"92","author":"Foley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1586\/14779072.2.3.431","article-title":"Achieving lipid goals in Europe: how large is the treatment gap?","volume":"2","author":"Schwandt","year":"2004","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2003.10.004","article-title":"Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study","volume":"147","author":"Schuster","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"issue":"Suppl.","key":"10.1016\/j.atherosclerosis.2006.12.001_bib18","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of rosuvastatin 10 to 40milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib19","unstructured":"Galson SK, Food and Drug Administration, Department of Health & Human Services. Re: Docket No. 2004P-0113\/CP1. Letter to Sidney M. Wolfe, Director Health Research Group; March 11, 2005. Available at: http:\/\/www.fda.gov\/cder\/drug\/infopage\/rosuvastatin\/crestor_CP.pdf."},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjcard.2004.06.049","article-title":"Safety of rosuvastatin","volume":"94","author":"Shepherd","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib21","doi-asserted-by":"crossref","first-page":"114.","DOI":"10.1016\/S1567-5688(05)80451-9","article-title":"Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: economic analysis of the POLARIS study","volume":"6","author":"Miller","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","article-title":"Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease","volume":"91","author":"Schneck","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjcard.2003.08.009","article-title":"Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia","volume":"92","author":"Stein","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1567-5688(06)80113-3","article-title":"Apolipoproteins as predictors of cardiovascular risk in the collaborative atorvastatin diabetes study (CARDS)","volume":"7","author":"Durrington","year":"2006","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1567-5688(06)80629-X","article-title":"Apolipoprotein B\/A1 ratio is a better predictor of coronary heart disease risk than is LDL\/HDL cholesterol ratio in the IDEAL study","volume":"7","author":"Olsson","year":"2006","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib30","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ahj.2004.01.020","article-title":"Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial","volume":"148","author":"Schwartz","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00019501-200403000-00008","article-title":"Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia","volume":"15","author":"Hunninghake","year":"2004","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib34","first-page":"S1","article-title":"Hypertriglyceridemia: management of atherogenic dyslipidemia","volume":"55","author":"Bersot","year":"2006","journal-title":"J Fam Pract"},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib35","unstructured":"Commonly requested therapeutic class and product information. IMS Health Web site. Available at: http:\/\/www.imshealth.com\/ims\/portal\/front\/articleC\/0,2777,6025_18731_77056778,00.html Accessed March 9, 2006. Source: IMS Health, IMS National Prescription Audit Plus\u2122, 2\/2006."},{"key":"10.1016\/j.atherosclerosis.2006.12.001_bib36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients","volume":"92","author":"Newman","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T23:23:28Z","timestamp":1547076208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915006007441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0021915006007441"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.12.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}